Brad Watts, senior vice president at the U.S. Chamber of Commerce’s Global Innovation Policy Center (GIPC), oversees the center’s day-to-day operations. He also leads the development and implementation of the Chamber’s U.S. and global intellectual property (IP) agenda to foster a political, legal, and economic environment where innovators and creators can invest in the next big thing for the benefit of Americans and the world.
Watts previously served as the Republican chief counsel on the Senate Judiciary Committee Subcommittee on Intellectual Property. There he was responsible for planning and implementing Senator Thom Tillis’ (R-NC) and the Republican party’s legislative portfolio on all aspects of IP law.
In the 116th Congress, when Senator Tillis was chairman of the subcommittee, Watts served as majority chief counsel and staff director for the Senate Judiciary Committee Subcommittee on Intellectual Property. He was responsible for implementing the senator’s legislative and oversight agenda on all aspects of America’s innovation economy.
During Watts’ tenure as majority chief counsel, the subcommittee held 17 legislative and oversight hearings and multiple staff briefings on IP issues, ranging from the state of patent eligibility law in America to reforming the Digital Millennium Copyright Act of 1998. Under his leadership, the subcommittee passed the CASE Act, the Trademark Modernization Act, and the Protecting Lawful Streaming Act, three landmark bills that collectively represent the largest changes to IP law since the Leahy-Smith America Invents Act.
Earlier, Watts was chief immigration counsel to then-Senate Judiciary Committee Chairman Chuck Grassley (R-IA). He began his career with former Senator Jeff Sessions (R-AL) as a legislative counsel on the Subcommittee on Immigration and the National Interest, handling civil rights and civil liberties law, general tort law, bankruptcy, telecommunications, and IP issues for the senator.
*****
A person listed as a contributor has spoken or otherwise participated in Federalist Society events, publications, or multimedia presentations. A person's appearance on this list does not imply any other endorsement or relationship between the person and the Federalist Society. In most cases, the biographical information on a person's "contributor" page is provided directly by the person, and the Federalist Society does not edit or otherwise endorse that information. The Federalist Society takes no position on particular legal or public policy issues. All expressions of opinion by a contributor are those of the contributor.
Medicare's New Drug Price Mandate: Healthcare & Innovation Implications
A Regulatory Transparency Project Webinar
Deep Dive Episode 89 – The New DOJ-USPTO-NIST Policy Statement on Remedies for Infringement of Standard-Essential Patents
Regulatory Transparency Project Event Podcast
TeleforumMedicare's New Drug Price Mandate: Healthcare & Innovation Implications
A Regulatory Transparency Project Webinar
On January 17, the Biden-Harris Administration added 15 new drugs, including Ozempic, to the list of...
Medicare's New Drug Price Mandate: Healthcare & Innovation Implications
A Regulatory Transparency Project Webinar
On January 17, the Biden-Harris Administration added 15 new drugs, including Ozempic, to the list of...
Deep Dive Episode 89 – The New DOJ-USPTO-NIST Policy Statement on Remedies for Infringement of Standard-Essential Patents
Regulatory Transparency Project Event Podcast
In December 2019, the Department of Justice, the U.S. Patent & Trademark Office, and the...